Tango Therapeutics, Inc. (TNGX)
23.78
+0.41
(+1.75%)
USD |
NASDAQ |
Sep 11, 16:00
23.76
-0.02
(-0.08%)
After-Hours: 20:00
Tango Therapeutics Enterprise Value : 3.022B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 3.022B |
| September 10, 2026 | 2.953B |
| September 09, 2026 | 3.059B |
| September 08, 2026 | 2.840B |
| September 04, 2026 | 2.810B |
| September 03, 2026 | 2.850B |
| September 02, 2026 | 2.776B |
| September 01, 2026 | 2.781B |
| August 31, 2026 | 2.864B |
| August 28, 2026 | 2.948B |
| August 27, 2026 | 3.275B |
| August 26, 2026 | 3.307B |
| August 25, 2026 | 3.189B |
| August 24, 2026 | 3.145B |
| August 21, 2026 | 3.039B |
| August 20, 2026 | 2.977B |
| August 19, 2026 | 3.261B |
| August 18, 2026 | 3.302B |
| August 17, 2026 | 3.276B |
| August 14, 2026 | 3.329B |
| August 13, 2026 | 3.337B |
| August 12, 2026 | 3.325B |
| August 11, 2026 | 3.453B |
| August 10, 2026 | 3.677B |
| August 07, 2026 | 3.576B |
| Date | Value |
|---|---|
| August 06, 2026 | 3.901B |
| August 05, 2026 | 3.866B |
| August 04, 2026 | 3.962B |
| August 03, 2026 | 3.600B |
| July 31, 2026 | 3.595B |
| July 30, 2026 | 3.660B |
| July 29, 2026 | 3.371B |
| July 28, 2026 | 3.505B |
| July 27, 2026 | 3.517B |
| July 24, 2026 | 3.502B |
| July 23, 2026 | 3.640B |
| July 22, 2026 | 3.749B |
| July 21, 2026 | 3.904B |
| July 20, 2026 | 3.655B |
| July 17, 2026 | 3.827B |
| July 16, 2026 | 3.672B |
| July 15, 2026 | 4.112B |
| July 14, 2026 | 4.010B |
| July 13, 2026 | 3.793B |
| July 10, 2026 | 4.248B |
| July 09, 2026 | 4.157B |
| July 08, 2026 | 4.177B |
| July 07, 2026 | 4.090B |
| July 06, 2026 | 4.059B |
| July 02, 2026 | 3.978B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Revolution Medicines, Inc. | 40.91B |
| Beam Therapeutics, Inc. | 1.572B |
| Erasca, Inc. | 4.739B |
| NovelStem International Corp. | 2.190M |
| Brainstorm Cell Therapeutics, Inc. | 13.27M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.34M |
| Total Expenses (Quarterly) | 55.34M |
| EPS Diluted (Quarterly) | -0.3692 |
| Earnings Yield | -3.52% |
| Normalized Earnings Yield | -3.522 |